Cryoport, Inc.
NASDAQ•CYRX
CEO: Mr. Jerrell W. Shelton
Sector: Industrials
Industry: Integrated Freight & Logistics
Listing Date: 2005-08-22
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Contact Information
Market Cap
$503.67M
P/E (TTM)
7.5
30.6
Dividend Yield
--
52W High
$11.44
52W Low
$4.58
52W Range
Rank69Top 93.9%
1.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2024 Data
Revenue
$44.23M-21.94%
4-Quarter Trend
EPS
-$0.18+637.19%
4-Quarter Trend
FCF
-$1.27M+20.36%
4-Quarter Trend
2024 Q3 Earnings Highlights
Key Highlights
Revenue Growth Strong Total revenue $44.2M USD for Q3, up 15.4% from $38.3M USD. Life Sciences Services revenue grew 15.9%.
Gross Margin Expansion Noted Nine months gross margin reached 46.9% USD, a 22.3% increase over prior period. Cost of revenue grew slower.
Cash Position Significantly Improved Cash and equivalents $255.8M USD as of September 30, 2025, reflecting proceeds from CRYOPDP divestiture.
Continuing Operations Loss Narrowed Nine months loss from continuing operations $(25.4M) USD, significantly better than prior year's $(87.5M) USD loss.
Risk Factors
Continuing Operations Remain Unprofitable Q3 loss from continuing operations was $(6.7M) USD, indicating ongoing profitability challenges outside divestiture gains.
Goodwill Impairment Potential MVE reporting unit goodwill fully impaired in 2024 due to sustained share price decrease and performance concerns.
Future Capital Funding Required Management recognizes need for additional capital via equity or debt to fund operations until sustained profitability.
Foreign Exchange Fluctuation Exposure Foreign currency risk exists on cash balances; 20% adverse change could impact cash by $5.0M USD.
Outlook
Divestiture Strategic Shift Complete Completed CRYOPDP divestiture for $133.0M USD, enhancing focus on EMEA/APAC growth strategy alignment.
Focus on Core Life Sciences Strategy emphasizes supporting Cell and Gene Therapy development through advanced logistics and product offerings.
Share Repurchase Authorization Available Approximately $65.9M USD repurchase authorization remains available under existing Repurchase Programs as of period end.
Investment in Growth Initiatives Expect to incur significant expenses near term for new supply chain initiatives and geographic expansion efforts.
Peer Comparison
Revenue (TTM)
FWRD$2.50B
TWI$1.80B
$1.64B
Gross Margin (Latest Quarter)
89.3%
48.2%
EBF30.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| FWRD | $812.07M | -6.9 | -71.5% | 16.9% |
| TWI | $537.75M | -87.8 | -1.1% | 33.0% |
| ZIP | $512.29M | -14.0 | 284.6% | 2.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-9.4%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention
Research & Insights
Next earnings:Mar 3, 2026
EPS:-$0.19
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2024
Period End: Sep 30, 2025|Filed: Nov 6, 2025|Revenue: $44.23M-21.9%|EPS: $-0.18+637.2%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2025|Filed: Aug 12, 2025|Revenue: $45.45M+14.5%|EPS: $2.05-226.5%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2025|Filed: May 8, 2025|Revenue: $41.04M-24.8%|EPS: $-0.28-34.9%BeatForm 10-K - FY 2023
Period End: Dec 31, 2024|Filed: Mar 7, 2025|Revenue: $233.26M-2.1%|EPS: $-2.21-12.7%MissForm 10-Q - Q3 2023
Period End: Sep 30, 2024|Filed: Nov 7, 2024|Revenue: $56.66M+0.9%|EPS: $-0.02-92.2%BeatForm 10-Q - Q2 2023
Period End: Jun 30, 2024|Filed: Aug 8, 2024|Revenue: $39.71M-30.4%|EPS: $-1.62+285.7%MissForm 10-Q - Q1 2023
Period End: Mar 31, 2024|Filed: May 8, 2024|Revenue: $54.59M-13.1%|EPS: $-0.43+168.8%MissForm 10-K - FY 2022
Period End: Dec 31, 2023|Filed: Mar 13, 2024|Revenue: $233.26M-1.7%|EPS: $-2.21-137.6%Miss